[1. NDISANG JF., VANNACCI A., RASTOGI S. Insulin resistance, type 1 and type 2 diabetes, and related complications 2017. J Diabetes Res. 2017; 2017:1478294.10.1155/2017/1478294]Search in Google Scholar
[2. TAYLOR R. Insulin resistance and type 2 diabetes. Diabetes. 2012; 61(4):778–9.10.2337/db12-0073]Search in Google Scholar
[3. NICKERSON HD., DUTTA S. Diabetic complications: current challenges and opportunities. J Cardiovasc Transl Res. 2012; 5(4):375–9.10.1007/s12265-012-9388-1]Search in Google Scholar
[4. PAPATHEODOROU K., BANACH M., BEKIARI E., RIZZO M., EDMONDS M. Complications of diabetes 2017. J Diabetes Res. 2018; 2018:3086167.10.1155/2018/3086167]Search in Google Scholar
[5. SHAN PF., LI Q., KHAMAISI M., QIANG GF. Type 2 Diabetes mellitus and macrovascular complications. Int J Endocrinol. 2017; 2017:4301461.10.1155/2017/4301461]Search in Google Scholar
[6. JING X., CHEN J., DONG Y., HAN D., ZHAO H., WANG X., et al. Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis. Health Qual Life Outcomes. 2018; 16(1):189.10.1186/s12955-018-1021-9]Search in Google Scholar
[7. TRIKKALINOU A., PAPAZAFIROPOULOU AK., MELIDONIS A. Type 2 diabetes and quality of life. World J Diabetes. 2017; 8(4):120–9.10.4239/wjd.v8.i4.120]Search in Google Scholar
[8. WOU C., UNWIN N., HUANG Y., ROGLIC G. Implications of the growing burden of diabetes for premature cardiovascular disease mortality and the attainment of the Sustainable Development Goal target 3.4. Cardiovasc Diagn Ther. 2019; 9(2):140–9.10.21037/cdt.2018.09.04]Search in Google Scholar
[9. GBD 2017 DISEASE AND INJURY INCIDENCE AND PREVALENCE COLLABORATORS. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1789–858.10.1016/S0140-6736(18)32279-7]Search in Google Scholar
[10. INTERNATIONAL DIABETES FEDERATION. IDF Diabetes Atlas. 9 ed, 2019.]Search in Google Scholar
[11. GBD 2017 CAUSES OF DEATH COLLABORATORS. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736–88.10.1016/S0140-6736(18)32203-7]Search in Google Scholar
[12. KHAN MAB., HASHIM MJ., KING JK., GOVENDER RD., MUSTAFA H., Al KAABI J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020; 10(1):107–11.10.2991/jegh.k.191028.001]Search in Google Scholar
[13. SEURING T., ARCHANGELIDI O., SUHRCKE M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015; 33(8):811–31.10.1007/s40273-015-0268-9451963325787932]Search in Google Scholar
[14. MARIN-PENALVER JJ., MARTIN-TIMON I., SEVILLANO-COLLANTES C., DEL CANIZO-GOMEZ FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016; 7(17):354–95.10.4239/wjd.v7.i17.354502700227660695]Search in Google Scholar
[15. INZUCCHI SE., BERGENSTAL RM., BUSE JB., DIAMANT M., FERRANNINI E., NAUCK M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–9.10.2337/dc14-244125538310]Search in Google Scholar
[16. CHAUDHURY A., DUVOOR C., REDDY DENDI VS., KRALETI S., CHADA A., RAVILLA R., et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017; 8:6.10.3389/fendo.2017.00006525606528167928]Search in Google Scholar
[17. TRAN L., ZIELINSKI A., ROACH AH., JENDE JA., HOUSEHOLDER AM., COLE EE., et al. Pharmacologic treatment of type 2 diabetes: oral medications. Ann Pharmacother. 2015; 49(5):540–56.10.1177/106002801455828925667196]Search in Google Scholar
[18. LEE BW., KIM JH., KO SH., HUR KY., KIM NH., RHEE SY., et al. Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017. Diabetes Metab J. 2017; 41(5):367–73.10.4093/dmj.2017.41.5.367566367529086534]Search in Google Scholar
[19. LARKIN ME., CAPASSO VA., CHEN CL., MAHONEY EK., HAZARD B., CAGLIERO E., et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008; 34(3):511–7.10.1177/014572170831786918535324]Search in Google Scholar
[20. POLONSKY WH., FISHER L., GUZMAN S., VILLA-CABALLERO L., EDELMAN SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005; 28(10):2543–5.10.2337/diacare.28.10.254316186296]Search in Google Scholar
[21. SONG Y., KU BJ., CHO J., JUN Y., KIM B., NAM S. The prevalence of insulin refusal and psychological insulin resistance among Korean patients with type 2 diabetes mellitus. Ann Transl Med. 2019; 7(23):760.10.21037/atm.2019.11.77698997432042776]Search in Google Scholar
[22. TAN WL., ASAHAR SF., HARUN NL. Insulin therapy refusal among type II diabetes mellitus patients in Kubang Pasu district, the state of Kedah, Malaysia. Singapore Med J. 2015; 56(4):224–7.10.11622/smedj.2014170441510325532511]Search in Google Scholar
[23. WOUDENBERG YJ., LUCAS C., LATOUR C., SCHOLTE OP REIMER WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012; 29(6):796–802.10.1111/j.1464-5491.2011.03552.x22150962]Search in Google Scholar
[24. NG CJ., LAI PS., LEE YK., AZMI SA., TEO CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015; 69(10):1050–70.10.1111/ijcp.1269126147376]Search in Google Scholar
[25. NGAMJARUS C., CHONGSUVIVATWONG V., McNEIL E. n4Studies: sample size calculation for an epidemiological study on a smart device. Siriraj Med J. 2016; 68:160–70.]Search in Google Scholar
[26. ABU HASSAN H., TOHID H., MOHD AMIN R., LONG BIDIN MB., MUTHUPALANIAPPEN L., OMAR K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013; 14:164.10.1186/1471-2296-14-164423161124164794]Search in Google Scholar
[27. BANERJEE A., CHITNIS UB., JADHAV SL., BHAWALKER JS., CHAUDHURY S. Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2009; 18(2):127–31.10.4103/0972-6748.62274299619821180491]Search in Google Scholar
[28. BIN RSHEED A., CHENOWETH I. Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes. 2017; 8(1):28–39.10.4239/wjd.v8.i1.28523781528138362]Search in Google Scholar
[29. KABADI UM. Starting insulin in type 2 diabetes: overcoming barriers to insulin therapy. Int J Diabetes Dev Ctries. 2008; 28(2):65–8.10.4103/0973-3930.43102277200619902051]Search in Google Scholar
[30. RUSSELL-JONES D., POUWER F., KHUNTI K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018; 20(3):488–96.10.1111/dom.13132583693329053215]Search in Google Scholar
[31. ALLEN NA., ZAGARINS SE., FEINBERG RG., WELCH G.. Treating psychological insulin resistance in type 2 diabetes. J Clin Transl Endocrinol. 2016; 7:1–6.10.1016/j.jcte.2016.11.005]Search in Google Scholar
[32. KAPOOR U., RAMASAMY G., SELVARAJ K., SAHOO JP., KAR SS. Does one-to-one demonstration with insulin pads by health-care providers improves the insulin administration techniques among diabetic patients of a tertiary care teaching hospital in South India? Indian J Endocrinol Metab. 2016; 20(6):767–71.10.4103/2230-8210.192904510555827867877]Search in Google Scholar
[33. DAVIDSON MB. Insulin therapy: a personal approach. Clin Diabetes. 2015; 33(3):123–35.10.2337/diaclin.33.3.123450394126203205]Search in Google Scholar
[34. McCAMBRIDGE J., WITTON J., ELBOURNE DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014; 67(3):267–77.10.1016/j.jclinepi.2013.08.015396924724275499]Search in Google Scholar
[35. RAKEL RE. Improving patient acceptance and adherence in diabetes management: a focus on insulin therapy. Adv Therapy. 2009; 26(9):838–46.10.1007/s12325-009-0061-219768641]Search in Google Scholar
[36. DAL-RE R., JANIAUD P., IOANNIDIS JPA. Real-world evidence: how pragmatic are randomized controlled trials labeled as pragmatic? BMC Med. 2018; 16(1):49.10.1186/s12916-018-1038-2588339729615035]Search in Google Scholar
[37. ZWARENSTEIN M., TREWEEK S., GAGNIER JJ., ALTMAN DG., TUNIS S., HAYNES B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008; 337:a2390.10.1136/bmj.a2390326684419001484]Search in Google Scholar